Related references
Note: Only part of the references are listed.In Vitro and In Vivo Activities of β-Lactams in Combination with the Novel β-Lactam Enhancers Zidebactam and WCK 5153 against Multidrug-Resistant Metallo-β-Lactamase-Producing Klebsiella pneumoniae
Bartolome Moya et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2019)
In Vivo Efficacy of WCK 5222 (Cefepime-Zidebactam) against Multidrug-Resistant Pseudomonas aeruginosa in the Neutropenic Murine Thigh Infection Model
Marguerite L. Monogue et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2019)
In Vivo Efficacy of Humanized WCK 5222 (Cefepime-Zidebactam) Exposures against Carbapenem-Resistant Acinetobacter baumannii in the Neutropenic Thigh Model
Safa S. Almarzoky Abuhussain et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2019)
Plasma and Intrapulmonary Concentrations of Cefepime and Zidebactam following Intravenous Administration of WCK 5222 to Healthy Adult Subjects
Keith A. Rodvold et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2018)
Antibiotic resistance rates for Pseudomonas aeruginosa clinical respiratory and bloodstream isolates among the Veterans Affairs Healthcare System from 2009 to 2013
Haley J. Appaneal et al.
DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE (2018)
Strategic Approaches to Overcome Resistance against Gram-Negative Pathogens Using β-Lactamase Inhibitors and β-Lactann Enhancers: Activity of Three Novel Diazabicyclooctanes WCK 5153, Zidebactam (WCK 5107), and WCK 4234
Krisztina M. Papp-Wallace et al.
JOURNAL OF MEDICINAL CHEMISTRY (2018)
Assessment of the In Vivo Efficacy of WCK 5222 (Cefepime-Zidebactam) against Carbapenem-Resistant Acinetobacter baumannii in the Neutropenic Murine Lung Infection Model
Lindsay M. Avery et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2018)
WCK 5222 (cefepime/zidebactam) antimicrobial activity tested against Gram-negative organisms producing clinically relevant β-lactamases
Helio S. Soder et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2017)
In vitro activity of cefepime/zidebactam (WCK 5222) against Gram-negative bacteria
David M. Livermore et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2017)
Intensive care unit-acquired pneumonia due to Pseudomonas aeruginosa with and without multidrug resistance
Laia Fernandez-Barat et al.
JOURNAL OF INFECTION (2017)
Activity of Ceftolozane-Tazobactam and Ceftazidime-Avibactam against Beta-Lactam-Resistant Pseudomonas aeruginosa Isolates
Romney M. Humphries et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2017)
Considerations for effect site pharmacokinetics to estimate drug exposure: concentrations of antibiotics in the lung
Keith A. Rodvold et al.
CURRENT OPINION IN PHARMACOLOGY (2017)
Ceftolozane-Tazobactam for the Treatment of Multidrug-Resistant Pseudomonas aeruginosa Infections: Clinical Effectiveness and Evolution of Resistance
Ghady Haidar et al.
CLINICAL INFECTIOUS DISEASES (2017)
WCK 5107 (Zidebactam) and WCK 5153 Are Novel Inhibitors of PBP2 Showing Potent β-Lactam Enhancer Activity against Pseudomonas aeruginosa, Including Multidrug-Resistant Metallo-β-Lactamase-Producing High-Risk Clones
Bartolome Moya et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2017)
Current evidence on hospital antimicrobial stewardship objectives: a systematic review and meta-analysis
Emelie C. Schuts et al.
LANCET INFECTIOUS DISEASES (2016)
Efficacies of Ceftazidime-Avibactam and Ceftazidime against Pseudomonas aeruginosa in a Murine Lung Infection Model
Seth T. Housman et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2014)
Pseudomonas aeruginosa Ventilator-associated Pneumonia Predictive Factors of Treatment Failure
Benjamin Planquette et al.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2013)
The Use of Cefepime for Treating AmpC β-Lactamase-Producing Enterobacteriaceae
Pranita D. Tamma et al.
CLINICAL INFECTIOUS DISEASES (2013)
Clinical Pharmacodynamics of Cefepime in Patients Infected with Pseudomonas aeruginosa
Jared L. Crandon et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2010)
Identifying Exposure Targets for Treatment of Staphylococcal Pneumonia with Ceftobiprole
Keith A. Rodvold et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2009)
Evaluation of area under the inhibitory curve (AUIC) and time above the minimum inhibitory concentration (T>MIC) as predictors of outcome for cefepime and ceftazidime in serious bacterial infections
Peggy S. McKinnon et al.
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS (2008)
The final goal: penicillin-binding proteins and the target of cephalosporins
R Fontana et al.
CLINICAL MICROBIOLOGY AND INFECTION (2000)
Share Paper
